Skip to main content
. 2021 Mar 3;35(2):1133–1139. doi: 10.21873/invivo.12359

Table I. Patient characteristics and univariate analysis.

graphic file with name in_vivo-35-1134-i0001.jpg

*The 3-year overall survival rate is 56.2%. OS: Overall survival; ECOG: Eastern Cooperative Oncology Group; BED: biologically effective dose; LMR: lymphocyte-to-monocyte ratio; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio